{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:08:52Z","timestamp":1782907732098,"version":"3.54.5"},"reference-count":21,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Approximately half of patients with chronic lymphocytic leukemia (CLL) will never require treatment; nonetheless, they are recommended life-long specialized follow-up (sFU). To prioritize health care resources, local hospital management implemented ending sFU in asymptomatic patients with CLL International Prognostic Index (CLL-IPI) and CLL without need of treatment (CLL-WONT) low-to-intermediate risk, who were covered by universal health care. To evaluate the feasibility and safety of ending sFU, we investigated 3-year clinical outcomes among 112 patients selected by clinical assessment to end sFU as compared with 88 patients selected to continue sFU. Patients who ended sFU were older, but otherwise lower risk compared with patients continuing sFU. Overall survival (OS) was similar in patients ending and continuing sFU (3-year OS, 87% and 80%, respectively; P\u00a0=\u00a0.16). Hospital visits per patient-year were lower (median 0.7 vs 4.3, P\u00a0&amp;lt; .0001) and time to first infection was longer (P\u00a0= .035) in patients ending sFU compared with those who continued sFU, including shorter in-hospital antimicrobial treatment (median 4 vs 12\u00a0days, respectively; P\u00a0= .026). Finally, 1 in 6 patients were rereferred, including 4 patients meeting international workshop on CLL criteria for need of treatment. This also resulted in a lower 3-year first treatment rate for patients ending sFU compared with patients continuing sFU (4% vs 23%, respectively; P\u00a0&amp;lt;\u00a0.0001). In conclusion, it is feasible and safe to end sFU for patients with CLL who have low-to-intermediate risk CLL-IPI and CLL-WONT scores upon thorough clinical evaluation before ending sFU.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012382","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T02:32:06Z","timestamp":1709346726000},"page":"4449-4456","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-8106","authenticated-orcid":false,"given":"Christian","family":"Brieghel","sequence":"first","affiliation":[{"name":"1Department of Hematology, Copenhagen University Hospital \u2013 Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-3098","authenticated-orcid":false,"given":"Caspar","family":"da Cunha-Bang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Copenhagen University Hospital \u2013 Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindrich","family":"Mourek","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Copenhagen University Hospital \u2013 Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Kjeldsen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Copenhagen University Hospital \u2013 Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten U.","family":"Niemann","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Copenhagen University Hospital \u2013 Rigshospitalet, Copenhagen, Denmark"},{"name":"2Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"issue":"25","key":"2024082715203382700_bib1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024082715203382700_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncol"},{"issue":"21","key":"2024082715203382700_bib3","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2024082715203382700_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.leukres.2008.06.019","article-title":"The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia","volume":"33","author":"Shanafelt","year":"2009","journal-title":"Leuk Res"},{"issue":"3","key":"2024082715203382700_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.genhosppsych.2007.01.014","article-title":"Depression, anxiety and quality of life in a chronic lymphocytic leukemia cohort","volume":"29","author":"Levin","year":"2007","journal-title":"Gen Hosp Psychiatry"},{"issue":"6586","key":"2024082715203382700_bib6","doi-asserted-by":"crossref","first-page":"eaay9040","DOI":"10.1126\/science.aay9040","article-title":"Early detection of cancer","volume":"375","author":"Crosby","year":"2022","journal-title":"Science"},{"issue":"14","key":"2024082715203382700_bib7","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJMsr1905447","article-title":"Epidemiologic signatures in cancer","volume":"381","author":"Welch","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024082715203382700_bib8","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1097\/HS9.0000000000000890","article-title":"Why do we diagnose monoclonal B-cell lymphocytosis? Five questions","volume":"7","author":"Hibbs","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"2024082715203382700_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2024082715203382700_bib10","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2024082715203382700_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/ejh.13743","article-title":"Identifying patients with chronic lymphocytic leukemia without need of treatment: end of endless watch and wait?","volume":"108","author":"Brieghel","year":"2022","journal-title":"Eur J Haematol"},{"issue":"1","key":"2024082715203382700_bib13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2147\/CLEP.S99486","article-title":"The Danish National Chronic Lymphocytic Leukemia Registry","volume":"8","author":"da Cunha-Bang","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2024082715203382700_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/CLEP.S17901","article-title":"Existing data sources for clinical epidemiology: the clinical laboratory information system (LABKA) research database at Aarhus University, Denmark","volume":"3","author":"Grann","year":"2011","journal-title":"Clin Epidemiol"},{"issue":"5","key":"2024082715203382700_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2022016147","article-title":"Patients with CLL have a lower risk of death from COVID-19 in the Omicron era","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024082715203382700_bib16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","article-title":"Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open-label, randomised, phase 2 trial","volume":"23","author":"Kater","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7762","key":"2024082715203382700_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-019-1252-x","article-title":"Growth dynamics in naturally progressing chronic lymphocytic leukaemia","volume":"570","author":"Gruber","year":"2019","journal-title":"Nature"},{"key":"2024082715203382700_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s43856-022-00117-4","article-title":"Pre-diagnostic trajectories of lymphocytosis predict time to treatment and death in patients with chronic lymphocytic leukemia","volume":"2","author":"Andersen","year":"2022","journal-title":"Commun Med (Lond)"},{"issue":"7","key":"2024082715203382700_bib19","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3324\/haematol.2017.182006","article-title":"Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study","volume":"103","author":"Andersen","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"2024082715203382700_bib20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.24660","article-title":"Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI","volume":"92","author":"Delgado","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"2024082715203382700_bib21","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3324\/haematol.2019.228171","article-title":"A\u00a0laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia","volume":"105","author":"Cohen","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2024082715203382700_bib22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41467-019-14225-8","article-title":"Machine learning can identify newly diagnosed patients with CLL at high risk of infection","volume":"11","author":"Agius","year":"2020","journal-title":"Nat Commun"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4449\/2239729\/blooda_adv-2023-012382-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4449\/2239729\/blooda_adv-2023-012382-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:20:51Z","timestamp":1724772051000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/16\/4449\/515174\/It-is-feasible-and-safe-to-stop-specialized-follow"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":21,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012382","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}